Publicaciones en las que colabora con FRANCISCO JAVIER DOLCET ROCA (25)
2016
-
Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer
Oncotarget, Vol. 7, Núm. 19, pp. 26979-26991
2014
-
Optimal protocol for PTEN immunostaining; Role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues
Human Pathology, Vol. 45, Núm. 3, pp. 522-532
-
Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma
Laboratory Investigation, Vol. 94, Núm. 6, pp. 608-622
2013
-
An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias
DMM Disease Models and Mechanisms, Vol. 6, Núm. 3, pp. 710-720
2011
-
FGFR2 alterations in endometrial carcinoma
Modern Pathology, Vol. 24, Núm. 11, pp. 1500-1510
-
KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels
American Journal of Pathology, Vol. 178, Núm. 4, pp. 1529-1543
-
Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma
Human Pathology, Vol. 42, Núm. 2, pp. 185-193
2010
-
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms
European Journal of Cancer, Vol. 46, Núm. 4, pp. 836-850
2009
-
A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma
Analytical and Quantitative Cytology and Histology, Vol. 31, Núm. 4, pp. 217-226
-
CK2β is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation
American Journal of Pathology, Vol. 174, Núm. 1, pp. 287-296
-
Molecular pathology of endometrial carcinoma: Practical aspects from the diagnostic and therapeutic viewpoints
Journal of Clinical Pathology, Vol. 62, Núm. 9, pp. 777-785
2008
-
CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells
Oncogene, Vol. 27, Núm. 18, pp. 2513-2524
-
Loss of heterozygosity in endometrial carcinoma
International Journal of Gynecological Pathology, Vol. 27, Núm. 3, pp. 305-317
-
Nuclear factor-κB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma
Human Pathology, Vol. 39, Núm. 7, pp. 994-1001
-
Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma
Modern Pathology, Vol. 21, Núm. 6, pp. 691-699
-
Targeted therapies in gynecologic cancers and melanoma
Seminars in Diagnostic Pathology, Vol. 25, Núm. 4, pp. 262-273
2007
-
Nuevas dianas terapéuticas en el melanoma
Piel, Vol. 22, Núm. 4, pp. 205-211
2006
-
Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines
Melanoma Research, Vol. 16, Núm. 2, pp. 127-135
-
PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations
Human Pathology, Vol. 37, Núm. 11, pp. 1465-1472
-
Proteasome inhibitors induce death but activate NF-κB on endometrial carcinoma cell lines and primary culture explants
Journal of Biological Chemistry, Vol. 281, Núm. 31, pp. 22118-22130